Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
N
376930
vs
K
KOSPI 200
Over the past 12 months, Noul Co Ltd has underperformed KOSPI 200, delivering a return of -89% compared to KOSPI 200's +56% growth.
Stocks Performance
376930 vs KOSPI 200
Performance Gap
376930 vs KOSPI 200
Performance By Year
376930 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Noul Co Ltd
Glance View
Noul Co Ltd develops blood-testing systems that help labs analyze blood samples faster and with less manual work. Its main product is an AI-based diagnostic platform that reads blood smears and other samples, then helps identify diseases such as blood disorders and infections. The company sells the instruments, disposable test cartridges, and software that work together as a package. Its customers are hospitals, clinical laboratories, and other medical testing centers that need reliable blood analysis without building large in-house expertise. Noul makes money by selling its devices and by recurring sales of test cartridges and related consumables used each time a sample is run. That mix matters because the instruments place the system, while the cartridges create repeat business. What makes Noul different is that it sits between traditional lab equipment and software. Instead of just selling a machine or just selling software, it combines both so a lab can process samples with more automation and less dependence on skilled human review. That gives the company a role in modernizing routine diagnostic testing, especially in places where labs want faster, standardized blood analysis.